1417526-69-2

Upstream product

• 1417526-66-9 4'-(trifluoromethyl)biphenyl-4-carbohydrazide 
• 1417526-67-0 4-ethyl-5-(4'-(trifluoromethyl)biphenyl-4-yl)-4H-1,2,4-triazole-3-thiol 
• 127783-73-7 methyl 4’-(trifluoromethyl)-[1,1’-biphenyl]-4-carboxylate 
• 195457-71-7 4-[4-(trifluoromethyl)phenyl]benzoic acid 

Downstream Products

• 1417527-29-7 1-((4-ethyl-5-(4'-(trifluoromethyl)biphenyl-4-yl)-4H-1,2,4-triazol-3-yl)methyl)-2-(4-fluorobenzylthio)-6,7-dihydro-1H-cyclopenta[d]pyrimidin-4(5H)-one 
• 1417526-71-6 (4-ethyl-5-(4'-(trifluoromethyl)biphenyl-4-yl)-4H-1,2,4-triazol-3-yl)methanamine 
• 1417526-73-8 1-((4-ethyl-5-(4'-(trifluoromethyl)biphenyl-4-yl)-4H-1,2,4-triazol-3-yl)methyl)-2-thioxo-2,3,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-4(5H)-one 
• 1417527-30-0 1-((4-ethyl-5-(4'-(trifluoromethyl)biphenyl-4-yl)-4H-1,2,4-triazol-3-yl)methyl)-2-(4-methoxybenzylthio)-6,7-dihydro-1H-cyclopenta[d]pyrimidin-4(5H)-one 

Relevant academic research and scientific papers

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the field of pharmaceutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) and a preparation method thereof, a pharmaceutical composition with the compounds as active components, and a use of the azole compounds and the pharmaceutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as defined in the specification.

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the filed of pharmarcutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) amd a preparation method thereof, a pharmarcutical composition with the compounds as active components, and a use of the azole compounds and the pharmarcutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as deinfed in the specifictaion.